←Back to list

OM1

Developer of an outcome management platform designed to provide measurement, comparison, and prediction of treatment out
Developer of an outcome management platform designed to provide measurement, comparison, and prediction of treatment outcomes.
Outcome Management (Healthcare) 📍 Boston, MA Founded 2015
Current Valuation
$855M
as of 2021-Q3
PRIVATE

QL Price

$855M
0% vs last round
QuantLogix's current estimate for OM1, published 2026-09-27 — in line with the last disclosed round of $855M (2021-Q3).
Confidence
low
Basis
round anchored
What backs this price
Last disclosed round $855M 2021-Q3 weight 0.03
How this price has held up
No round has priced for OM1 since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-27 and will be graded against the next priced round. See the full accuracy record →
How to actually get exposure to OM1 →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, OM1, 2026-09-27 (dcd02843b4d1bc8a). The id pins this exact claim, so a citation stays checkable after the price moves. Model estimate for research — not a quote, target price, or investment advice.

IPO Outlookprivate

Is OM1 going public?
No. OM1 is private and has not filed to go public. There is no S-1 on file.
What is OM1's valuation in 2026?
OM1 is valued at $855M as of 2021-Q3, set by its Series D ($85M, Jul 2021). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has OM1 filed an S-1?
No public S-1 is on file for OM1.
How much has OM1 raised?
OM1 has raised $176.25M in total, most recently a Series D of $85M in Jul 2021.
Is OM1 publicly traded — can you buy OM1 stock?
No. OM1 is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for OM1 on its Pre-IPO Access Desk.
How to actually get exposure to OM1 →
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.

Company Profile

Founded
2015
HQ
Boston, MA
Employees
119
Total Raised
$176.25M
Last Round
Series D — $85M (Jul 2021)
IPO Status
private

Fundraising Status

Series D · $85M · 5y 2mo ago
privateTotal raised $176.25M

Latest Funding Round

RoundAmountDateLead InvestorPost-Money
Series D$85MJul 2021—$855M

Talent Signal

Hiring trend
▶ Hiring steady
0% vs 2026-08
Open roles
6
via careers page
Product-build share
83%
engineering, research, product, design
Trajectory
steady
heavy product build — 83% of open roles are product-building functions (engineering/research/product) — 3 of 6 open roles are medical.
Actively hiring with no tracked executive churn.
Open roles by month
Open roles by month6Aug '266Sep '26
Open roles by function
Open roles by functionClinical & Science3Research2Marketing1
■ product-building   ■ go-to-market / G&A
Research ProgramsClinical RegistriesClinical Datasets & Insights[Research Programs](https://www.om1.com/research-programs/)[Clinical Registries](https://www.om1.com/our-solutions/clinical-registries/)Om1 Brand Abstract Blue Image
Counted from OM1's live job board as of 2026-09-16; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
MedicalHealth CareInformation TechnologyBig Data
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2021-Q3. Refreshed quarterly.